Role of human and animal PET studies in drug development

International Congress Series

Volumn 1265, Issue C, 2004, Pages 3-11

  Lammertsma, Adriaan A ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Animal models of disease; Drug development; Pharmacokinetics; Positron emission tomography; Receptor occupancy

Indexed keywords

EID: 79955654765     PISSN: 05315131     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.ics.2004.03.026     Document Type: Article

References (34)

1. Phelps, M.E., Mazziotta, J, Schelbert, H.R., Positron Emission Tomography and Autoradiography. 1986, Raven Press, New York.
2. Valk, P.E., et al. Positron Emission Tomography. 2003, Springer-Verlag, New York.
3. Jones, T, The role of positron emission tomography within the spectrum of medical imaging. Eur. J. Nucl. Med. 23 (1996), 207–211.
4. Comar, D, (eds.) PET for Drug Development and Evaluation, 1995, Kluwer Academic Publishing, Dordrecht.
5. Eckelman, W.C., Accelerating drug discovery and development through in vivo imaging. Nucl. Med. Biol. 29 (2002), 777–782.
6. Propper, D.J., et al. Use of positron emission tomography in pharmacokinetic studies to investigate therapeutic advantage in a phase I study of 120-hour intravenous infusion XR5000. J. Clin. Oncol. 21 (2003), 203–210.
7. Wollmer, P, et al. Measurement of pulmonary erythromycin concentration in patients with lobar pneumonia by means of positron tomography. Lancet 2 (1982), 1361–1364.
8. Anderson, H, et al. Measuring changes in human tumour vasculature in response to therapy using functional imaging techniques. Br. J. Cancer 85 (2001), 1085–1093.
9. 18F]-2-fluoro-2-deoxy-D-glucose and positron emission tomography: an overview of different analytical methods. Eur. J. Nucl. Med. 27 (2000), 731–743.
10. 18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. Eur. J. Cancer 35 (1999), 1773–1782.
11. 18F-FDG PET. J. Nucl. Med. 43 (2002), 1304–1309.
12. 18F]FDG uptake in breast cancer during chemotherapy: comparison of analytical methods. Eur. J. Nucl. Med. Mol. Imaging 30 (2003), 674–681.
13. 18F]-fluoro-D-glucose for response monitoring in locally advanced gastroesophageal cancer; a comparison of different analytical methods. Mol. Imaging Biol. 5 (2003), 337–346.
14. Wallhaus, T.R., et al. Myocardial free fatty acid and glucose use after varvedilol treatment in patients with congestive heart failure. Circulation 103 (2001), 2441–2446.
15. Kunnas, T.A., et al. Endothelial nitric oxide synthase genotype modulates the improvement of coronary blood flow by pravastatin: a placebo-controlled PET study. J. Mol. Med. 80 (2002), 802–807.
16. Heiss, W.D., et al. Quantitative neuroimaging for the evaluation of the effect of stroke treatment. Cerebrovasc. Dis. 8:Suppl. 2 (1998), 23–29.
17. Eberling, J.L., et al. Effect of estrogen on cerebral glucose metabolism in postmenopausal women. Neurology 55 (2000), 875–877.
18. 11C]citalopram as a radioligand for in vivo labelling of 5-hydroxytryptamine uptake sites. Nucl. Med. Biol. 19 (1992), 851–855.
19. 11C-raclopride. Psychopharmacology 112 (1993), 308–314.
20. Bench, C.J., et al. Measurement of human cerebral monoamine oxidase type B (MAO-B) activity with positron emission tomography (PET): a dose ranging study with the reversible inhibitor Ro 19-6327. Eur. J. Clin. Pharmacol. 40 (1991), 169–173.
21. 2 receptors by the neuroleptic ziprasidone (CP-88,059-01) determined by positron emission tomography. Psychopharmacology 124 (1996), 141–147.
22. 11C]raclopride binding with continuous infusion. J. Cereb. Blood Flow Metab. 17 (1997), 437–447.
23. Laruelle, M, Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J. Cereb. Blood Flow Metab. 20 (2000), 423–451.
24. 11C]raclopride: optimization and signal-to-noise considerations. J. Nucl. Med. 41 (2000), 522–530.
25. Ingvar, M, et al. Rapid feasibility studies of tracers for positron emission tomography: high-resolution PET in small animals with kinetic analysis. J. Cereb. Blood Flow Metab. 11 (1991), 926–931.
26. Hume, S.P., et al. Quantitation of carbon-11-labeled raclopride in rat striatum using positron emission tomography. Synapse 12 (1992), 47–54.
27. Chatziioannou, A.F., Molecular imaging of small animals with dedicated PET tomographs. Eur. J. Nucl. Med. 29 (2002), 98–114.
28. Boellaard, R, et al. Characterization of a single LSO crystal layer high resolution research tomograph. Phys. Med. Biol. 48 (2003), 1–20.
29. Hume, S.P., et al. The potential of high-resolution positron emission tomography to monitor striatal dopaminergic function in rat models of disease. J. Neurosci. Methods 67 (1996), 103–112.
30. Myers, R, Hume, S, Small animal PET. Eur. Neuropsychopharmacol. 12 (2002), 545–555.
31. Hume, S.P., Gunn, R.N., Jones, T, Pharmacological constraints associated with positron emission tomographic scanning of small laboratory animals. Eur. J. Nucl. Med. 25 (1998), 173–176.
32. Lammertsma, A.A., et al. PET scanners for small animals. J. Nucl. Med. 36 (1995), 2391–2392.
33. 11C]raclopride binding in rat striatum, quantified using PET. Synapse 21 (1995), 45–53.
34. 11C]verapamil as PET-tracers for measuring P-glycoprotein function: in vitro and in vivo evaluation. Nucl. Med. Biol. 30 (2003), 747–751.